309 related articles for article (PubMed ID: 36612267)
1. Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma.
Evdokimova V; Gassmann H; Radvanyi L; Burdach SEG
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612267
[TBL] [Abstract][Full Text] [Related]
2. Ewing Sarcoma-Derived Extracellular Vesicles Impair Dendritic Cell Maturation and Function.
Gassmann H; Schneider K; Evdokimova V; Ruzanov P; Schober SJ; Xue B; von Heyking K; Thiede M; Richter GHS; Pfaffl MW; Noessner E; Stein LD; Sorensen PH; Burdach SEG; Thiel U
Cells; 2021 Aug; 10(8):. PubMed ID: 34440851
[TBL] [Abstract][Full Text] [Related]
3. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
4. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
[TBL] [Abstract][Full Text] [Related]
5. Extracellular Vesicles in Reprogramming of the Ewing Sarcoma Tumor Microenvironment.
Pachva MC; Lai H; Jia A; Rouleau M; Sorensen PH
Front Cell Dev Biol; 2021; 9():726205. PubMed ID: 34604225
[TBL] [Abstract][Full Text] [Related]
6. Slit2 signaling stimulates Ewing sarcoma growth.
Suvarna K; Jayabal P; Ma X; Shiio Y
Genes Cancer; 2022; 13():88-99. PubMed ID: 36533189
[TBL] [Abstract][Full Text] [Related]
7. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
[TBL] [Abstract][Full Text] [Related]
8. EWS-FLI1 low Ewing sarcoma cells demonstrate decreased susceptibility to T-cell-mediated tumor cell apoptosis.
Bailey KM; Julian CM; Klinghoffer AN; Bernard H; Lucas PC; McAllister-Lucas LM
Oncotarget; 2019 May; 10(36):3385-3399. PubMed ID: 31164960
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA Content of Ewing Sarcoma Derived Extracellular Vesicles Leads to Biomarker Potential and Identification of a Previously Undocumented EWS-FLI1 Translocation.
Crow J; Samuel G; Farrow E; Gibson M; Johnston J; Guest E; Miller N; Pei D; Koestler D; Pathak H; Liang X; Mangels C; Godwin AK
Biomark Insights; 2022; 17():11772719221132693. PubMed ID: 36341281
[No Abstract] [Full Text] [Related]
10. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.
Heitzeneder S; Sotillo E; Shern JF; Sindiri S; Xu P; Jones R; Pollak M; Noer PR; Lorette J; Fazli L; Alag A; Meltzer P; Lau C; Conover CA; Oxvig C; Sorensen PH; Maris JM; Khan J; Mackall CL
J Natl Cancer Inst; 2019 Sep; 111(9):970-982. PubMed ID: 30698726
[TBL] [Abstract][Full Text] [Related]
11. EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.
Evans CH; Liu F; Porter RM; O'Sullivan RP; Merghoub T; Lunsford EP; Robichaud K; Van Valen F; Lessnick SL; Gebhardt MC; Wells JW
Clin Cancer Res; 2012 Oct; 18(19):5341-51. PubMed ID: 22879388
[TBL] [Abstract][Full Text] [Related]
12. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
13. IL-1 Family Members in Bone Sarcomas.
Landuzzi L; Ruzzi F; Pellegrini E; Lollini PL; Scotlandi K; Manara MC
Cells; 2024 Jan; 13(3):. PubMed ID: 38334625
[TBL] [Abstract][Full Text] [Related]
14. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
16. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
17. An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma Development.
Komura S; Semi K; Itakura F; Shibata H; Ohno T; Hotta A; Woltjen K; Yamamoto T; Akiyama H; Yamada Y
Stem Cell Reports; 2016 Apr; 6(4):592-606. PubMed ID: 26997645
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758
[TBL] [Abstract][Full Text] [Related]
19. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
[TBL] [Abstract][Full Text] [Related]
20. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
